Literature DB >> 32247845

Impact of Growth Discordance in Twins on Preeclampsia: based on chorionicity.

Ping Qiao1, Yan Zhao2, Xiang Jiang1, Chuanlu Xu1, Yingying Yang2, Yirong Bao1, Han Xie3, Hao Ying4.   

Abstract

BACKGROUND: Despite extensive investigations over the last decade, preeclampsia (PE) remains an unpredictable pregnancy complication causing perinatal morbidity and mortality worldwide, particularly in twin pregnancies.
OBJECTIVE: This study aimed to determine the relationship between growth discordance in twin pregnancies and the risk for PE, based on chorionicity. STUDY
DESIGN: This was a retrospective single-center study in which 2122 women with twin pregnancies who were admitted to a tertiary hospital between January 2013 and June 2016 were included. Growth discordance was defined as a twin birth weight difference ≥20%. Logistic regression models were used to analyze the associations between twin growth discordance and gestational hypertension-PE (GH-PE) risk. In addition to logistic regression analyses of all subjects, stratified modeling by twin chorionicity (dichorionic (DC) and monochorionic (MC)) was conducted. Further analysis was performed to estimate the associations between growth discordance degree and GH-PE risk in MC and DC twin pregnancies.
RESULTS: The prevalence of growth discordance was 17.6%. In all subjects, twin growth discordance was associated with increased risk of GH-PE risk. After stratified by twin chorionicity, growth discordance was associated with an increased risk for GH-PE (AOR=1.84; 95% CI, 1.26-2.67) and PE (AOR=1.82; 95% CI:1.21-2.73;), including mild PE (AOR=1.86; 95% CI: 1.02-3.37), severe PE (AOR=1.78; 95% CI: 1.06-2.97; P<0.05), and early-onset PE (AOR=2.98; 95% CI: 1.40-6.32) among DC twin pregnancy group; however, no significant association was found among MC twin pregnancy group. A 10% increment of growth discordance in DC twin pregnancy group was associated with an elevated risk for GH-PE (AOR=1.20; 95% CI: 1.02-1.41;) and PE (AOR=1.24; 95% CI: 1.04-1.48), including severe PE (AOR=1.28; 95% CI: 1.04-1.59), early-onset PE (AOR=1.47; 95% CI: 1.08-2.00), and no significant association was found among MC twin pregnancy.
CONCLUSIONS: Growth discordance is associated with a high risk for PE in DC but not MC twin pregnancy. Additionally, the prevalence of PE increases significantly with increasing degree of discordant growth, reflecting a dose-response relationship in DC twin pregnancy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chorionicity; Dichorionic twins; Growth discordance; Hypertensive disorders of pregnancy; Monochorionic twins; Preeclampsia; Twin pregnancy

Year:  2020        PMID: 32247845     DOI: 10.1016/j.ajog.2020.03.024

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Maternal Thyroid Function and Birth Weight in Twins.

Authors:  Xiao Song Liu; Xiu Juan Su; Guo Hua Li; Shi Jia Huang; Yang Liu; Han Xiang Sun; Qiao Ling Du
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

2.  Twin Growth Discordance and Risk of Postpartum Hemorrhage: A Retrospective Cohort Study.

Authors:  Xiuhong Cao; Ye Luo; Shuangqiong Zhou; Qingsong Zhao; Xuewei Qin; Zhiqiang Liu; Zhendong Xu
Journal:  Front Med (Lausanne)       Date:  2022-05-25

3.  Prediction of maternal complications and neonatal outcome in dichorionic diamniotic twins with fetal weight discordancy measured by ultrasonography.

Authors:  Hyun Mi Kim; Hyun-Hwa Cha; Won Joon Seong; Hye Jin Lee; Mi Ju Kim
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

4.  The association of hypertensive disorders of pregnancy with small for gestational age and intertwin birthweight discordance.

Authors:  Dongxin Lin; Caihong Luo Bd; Gengdong Chen; Dazhi Fan; Zheng Huang; Pengsheng Li; Shuzhen Wu; Shaoxin Ye Bd; Huiting Ma; Jiaming Rao; Huishan Zhang; Ting Chen; Meng Zeng; Xiaoling Guo; Zhengping Liu
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-20       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.